Savings Card Pharmacy Instructions

The Savings Card must be activated online or by telephone before it may be used. To activate the Savings Card, individuals must answer several questions to determine if they are eligible to participate in the Savings Card and, if an individual uses Medicare Part D for prescription drug coverage, the individual must agree that he or she (1) will not submit claims for the Drug to their Medicare Part D plan and (2) will not apply any amounts paid by an individual when using the Savings Card towards Medicare Part D true out-of-pocket (TrOOP) expenses. Eisai Inc. has entered into an agreement with McKesson to implement the Savings Card. McKesson processes pharmacy claims and relies on claims data to detect, in real time, attempted Savings Card use by individuals who are ineligible to participate in the Savings Card offer.

For Commercially Insured Patients:

To apply for the Savings Card for BELVIQ or BELVIQ XR:

Commercially insured beneficiaries must present the Savings Card for BELVIQ or BELVIQ XR to their pharmacists along with their Drug prescriptions. The Savings Card allows commercially insured beneficiaries to receive discounts on out-of-pocket costs (up to a maximum benefit of $160 per prescription), on up to 12 Drug prescriptions.

  • Process a coordination of benefits (COB) transaction using the patient’s prescription insurance for the primary claim.
  • Insured/Covered claims will process against the primary payer and the payer will accept the claim, giving the pharmacy an amount due to the patient. The pharmacy will submit to McKesson as a secondary with the other coverage code that indicates an approved claim by the payer (OCC 2/8).
  • Insured/NOT Covered claims will process against the primary payer and the payer will reject the claim (PA, NDC block, Not on formulary, not eligible, etc), not giving the pharmacy an amount due since the claim was rejected. The pharmacy will submit to McKesson as a secondary with the other coverage code that indicates a rejected claim by the payer (OCC 3) and will include the code of the block so we can identify the reason for rejection.

For Cash Pay & Medicare Part D Patients:

To apply for the Savings Card for BELVIQ or BELVIQ XR:

Cash Pay and Part D beneficiaries must present the Savings Card to their pharmacists along with their Drug prescriptions. The Savings Card allows Cash Pay and Part D Beneficiaries to receive discounts on out-of-pocket costs (up to a maximum benefit of $185 per prescription), on up to 12 Drug prescriptions.

  • Please use information from the Savings Card as the primary claim
  • The primary claim will reduce eligible patients’ out-of-pocket cost by up to ($185) per prescription if their copay does not cause the reimbursement to exceed the maximum for the Savings Card. Maximum reimbursement limits and tablet quantity limits apply.
  • For Part D Beneficiaries, advise patient that in using the Savings Card, patient agrees he or she will not submit a claim for reimbursement for the prescription to any state or federal health care program or other governmental program, and advise patient that any amounts paid by patient when using the Savings Card cannot be applied towards Medicare Part D true out-of-pocket (TrOOP) expenses.

By accepting the Savings Card when dispensing a prescription for the Drug to a Part D Beneficiary, the pharmacist certifies that he or she has not submitted and will not submit a claim for reimbursement for the prescription to any state or federal health care program or other governmental program.

View Clinical Video Presentation

PRODUCT INDICATION FOR BELVIQ® AND BELVIQ XR®

INDICATION

BELVIQ/BELVIQ XR is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).

Limitations of Use:

  • The safety and efficacy of coadministration of BELVIQ/BELVIQ XR with other products intended for weight loss, including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations, have not been established.
  • The effect of BELVIQ/BELVIQ XR on cardiovascular morbidity and mortality has not been established.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Pregnancy: BELVIQ/BELVIQ XR should not be taken during pregnancy or by women who are planning to become pregnant.
  • Hypersensitivity: Patients with prior hypersensitivity reactions to lorcaserin or to any of the product components should not take BELVIQ/BELVIQ XR. Hypersensitivity reactions have been reported.

Warnings and Precautions

  • Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)- like reactions: BELVIQ/BELVIQ XR is a serotonergic drug. The development of potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported during use of serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors, and selective serotonin reuptake inhibitors, tricyclic antidepressants, bupropion, triptans, dietary supplements such as St. John's Wort and tryptophan, drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors), dextromethorphan, lithium, tramadol, antipsychotics or other dopamine antagonists, particularly when used in combination. Patients should be monitored for the emergence of serotonin syndrome symptoms or NMS-like reactions, including agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting, diarrhea, and muscle rigidity. Treatment with BELVIQ/BELVIQ XR and any concomitant serotonergic or antidopaminergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
  • Valvular heart disease: Patients should not take BELVIQ/BELVIQ XR in combination with potent 5-HT2B receptor agonists that have been associated with regurgitant valvular heart disease (e.g., cabergoline). In clinical trials, 2.4% of patients taking BELVIQ and 2.0% of patients taking placebo developed valvular regurgitation: none of these patients were symptomatic. BELVIQ/BELVIQ XR should be used with caution in patients with congestive heart failure (CHF). Patients who develop signs and symptoms of valvular heart disease, including dyspnea, dependent edema, CHF, or a new cardiac murmur, should be evaluated and discontinuation of BELVIQ/BELVIQ XR should be considered.
  • Cognitive impairment: Impairment in attention, memory, somnolence, confusion, and fatigue have been reported in patients taking BELVIQ. Patients should not drive a car or operate heavy machinery until they know how BELVIQ/BELVIQ XR affects them.
  • Psychiatric disorders: The recommended daily dose should not be exceeded, as higher doses may cause euphoria, hallucination, and dissociation. Monitor patients for the development or worsening of depression, suicidal thoughts or behaviors, and/or any changes in mood. Discontinue BELVIQ/BELVIQ XR in patients who develop suicidal thoughts or behaviors.
  • Hypoglycemia: Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes mellitus who are being treated with antidiabetic medications, so measurement of blood sugar levels before and during treatment with BELVIQ/BELVIQ XR is recommended. Decreases in doses of antidiabetic medications or changes in medication regimen should be considered.
  • Priapism: Men who experience priapism should immediately discontinue BELVIQ/BELVIQ XR and seek emergency medical attention. BELVIQ/BELVIQ XR should be used with caution with erectile dysfunction medications. BELVIQ/BELVIQ XR should be used with caution in men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie's disease).
  • Heart rate decreases: Because BELVIQ/BELVIQ XR may cause a slow heartbeat, it should be used with caution in patients with a history of bradycardia or heart block greater than first degree.
  • Monitoring Considerations: Consider monitoring for CBC changes, signs and symptoms of prolactin excess, and pulmonary hypertension.

Most Common Adverse Reactions for BELVIQ®

  • In patients without diabetes: headache (17%), dizziness (9%), fatigue (7%), nausea (8%), dry mouth (5%), and constipation (6%).
  • In patients with diabetes: hypoglycemia (29%), headache (15%), back pain (12%), cough (8%), and fatigue (7%).

Most Common Adverse Reactions for BELVIQ XR®

  • Common side effects in patients on BELVIQ XR were similar to those seen in patients on BELVIQ.

Nursing Mothers

  • BELVIQ/BELVIQ XR should not be taken by women who are nursing.

BELVIQ®/BELVIQ XR® is a federally controlled substance (CIV) because it may be abused or lead to dependence.
For more information about BELVIQ®/BELVIQ XR®, see full Prescribing Information.